Journal of Multiple Sclerosis
ISSN - 2376-0389NLM - 101654564
Department of Neurology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
Research Article
Two-year Assessment of the Efficacy and Safety of Ocrelizumab in Switching Patients from Other Disease Modifying Therapies
Author(s): Terzi Murat, Boz Cavit, Demir Caner Feyz, Cilingir Vedat* and Helvaci Elif Merve
Objective: To evaluate the efficacy and safety of OCR in a real-world setting.
Methods: Clinical data for patients aged ≥ 18 years with relapsing forms of MS or Primary Progressive MS (PPMS) were retrospectively collected from medical records. The main efficacy outcomes were several relapses and a proportion of patients free from relapses, disability progression, and brain MRI activity (gadolinium [gd+] enhanced and new t2 lesions).
Results: A total of 460 patients were included: 246 with relapsing-remitting MS (RRMS), 196 Progressive Relapsing MS (PRMS), and 18 PPMS. The patients were 58.6% females with a mean age of 46.8 years. Fingolimod was the most commonly used disease-modifying therapy (DMT; 35.2%), followed by interferon β 1a+1b+glatiramer acetate (23.9%), and teriflunomide (10.4%) before OCR. The mean Ex.. View More»
DOI:
10.35248/2376-0389.22.9.12.475
